Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective.

about

Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective.

Item

http://www.wikidata.org/entity/Q52312388

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@en

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@nl

type

Item

label

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@en

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@nl

prefLabel

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@en

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@nl

P1476

Pharmabiotic Manipulation of t ...... rders: A Clinical Perspective.

@en

P2093

Eamonn M M Quigley

http://www.w3.org/2001/XMLSchema#string

Fanny Giron

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotics in early life alter the murine colonic microbiome and adiposity

A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB

Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia

Gut microbiota and gastrointestinal health: current concepts and future directions

Gut bacteria in health and disease

Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

Rifaximin therapy for patients with irritable bowel syndrome without constipation

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

P304

355-366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5056/JNM18004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29684976

http://www.w3.org/2001/XMLSchema#string

P932

6034666

http://www.w3.org/2001/XMLSchema#string